CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

The Comparison of Clinical Outcomes After Drug-Eluting Balloon and Drug-Eluting Stent Use for Left Main Bifurcation In-Stent Restenosis Lipoprotein(a) in Alzheimer, Atherosclerotic, Cerebrovascular, Thrombotic, and Valvular Disease: Mendelian Randomization Investigation Attenuated Mitral Leaflet Enlargement Contributes to Functional Mitral Regurgitation After Myocardial Infarction Sox17 Controls Emergence and Remodeling of Nestin-Expressing Coronary Vessels Everolimus-eluting stent implantation for unprotected left main coronary artery stenosis. The PRECOMBAT-2 (Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease) study Flow-Regulated Endothelial S1P Receptor-1 Signaling Sustains Vascular Development 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT) Cellular origin and developmental program of coronary angiogenesis Self-expandable sirolimus-eluting stents compared to second-generation drug-eluting stents for the treatment of the left main: A propensity score analysis from the SPARTA and the FAILS-2 registries Active factor XI is associated with the risk of cardiovascular events in stable coronary artery disease patients

Original Research2018 Nov 15;271:181-185.

JOURNAL:Int J Cardiol. Article Link

Heart rate, pulse pressure and mortality in patients with myocardial infarction complicated by heart failure

Dobre D, Kjekshus J, Rossignol P et al. Keywords: Heart failure; Heart rate; Myocardial infarction; Pulse pressure

ABSTRACT


OBJECTIVE - To assess the relationship between heart rate (HR), pulse pressure (PP), and their association with mortality in a population of high-risk patients following acute myocardial infarction (MI).


METHODS - We performed an analysis in 22,398 patients included in "The High-Risk Myocardial Infarction Database Initiative", a database of clinical trials evaluating pharmacologic interventions in patients with MI complicated by signs of heart failure (HF) or left ventricular dysfunction. We found an interaction between HR and PP. Based on median HR and median PP, patients were divided in four categories: (1) HR < 75 bpm and PP ≥ 50 mm Hg (reference), (2) HR < 75 bpm and PP < 50 mm Hg, (3) HR ≥ 75 bpm and PP ≥ 50 mm Hg, and (4) HR ≥ 75 bpm and PP < 50 mm Hg. The association between these categories and outcomes was studied using a Cox proportional hazard model.


RESULTS - After a median follow-up of 24 (18-33) months, 3561 (16%) patients died of all-causes and 3048 (14%) patients of cardiovascular (CV) causes. In multivariate analysis, patients from the fourth category had the highest risk of all-cause mortality (hazard ratio of 1.69; 95% CI: 1.53-1.86) and CV mortality (hazard ratio of 1.78; 95% CI: 1.60-1.97).


CONCLUSIONS - There is an interaction between HR and PP in patients with HF following MI, with the highest risk being conferred by a clinical status with both an elevated HR and a lower PP. These findings identify a high-risk population likely to require an aggressive diagnostic and management strategy.


Copyright © 2018. Published by Elsevier B.V.